generating decisions. They set the tone for the rest of the organisation. They cannot be told to do something they don't believe in. They need to lead in the development of efficient care." With NHS consultants in danger of losing out in the Griffiths management reforms (pp 1062, 1065), this message has an added urgency.
On Griffiths Enthoven's understated style is particularly devastating. "While I am sympathetic to the thrust of the report ... if the structure and incentives in the NHS are not changed more fundamentally, these recommendations are not likely to change much." For those grappling with the consequences of this "reform"-described as the biggest reorganisation the NHS has undergone-these words will bring no comfort. He identifies national uniformity and political haste as stultifying the aims of the management changes. With the departure of Kenneth Clarke from the Department of Health and Social Security the pressure for haste may lessen-though much damage has already been done.3 Even so, the Whitehall tradition of uniformity will be hard to overcome. Enthoven sees the solution in wider but more effective use of competitive tendering for catering, cleaning, and laundry services-the "entering wedge for a great deal of management improvement"; the purchase by districts of private sector medical care when this can be bought at a "good price"; a widespread use of pilot schemes before changes are introduced; and-the most provocative proposal of all-the substitution of positive incentives for existing perverse incentives, with the introduction of an "internal market model" for the NHS.
What does this last suggestion mean? The aim would be to enable managers to use resources most efficiently and this would be achieved as follows. Each district would receive RAWP based per capita revenue and capital allowances and would be responsible, as now, for providing and paying for comprehensive care for its resident population. It would be paid for emergency services to "outsiders" at a standard cost and for non-emergency services at negotiated prices. Hence in effect each authority would resemble an American health maintenance organisation (p 1068). Pay and working conditions would preferably be negotiated locally. Consultants and general practitioners would be contracted to district authorities, which could negotiate variable term contracts with appropriate incentives. Districts would be allowed, within limits, to borrow at government long term interest rates and to keep the proceeds of property sales. Services and assets could be bought and sold between districts, which would also be free to introduce management innovations.
Enthoven believes that such a market model would force the development of proper costing schemes and create much more cost efficiency and cost sensitivity among health authorities. He acknowledges that the model lacks incentives for decisions to be taken in the best interests of patients rather than of the authority. Though attracted by the idea of the patient choice available in America through competing hospital maintenance organisations-in themselves mini NHS's-he accepts that this would not be workable in Britain. But patients would be no worse off than they are already, and if the internal market model was found to be effective-presumably after suitable pilot studies-patients should benefit from a more effective and locally oriented service.
Medicopoliticians may well reject Enthoven's diagnosis and suggested treatment of the NHS's management ills. Ideological opponents of the private sector as well as sceptics who doubt its capabilities will also be critical. But, even shorn of its suggested links with the private sector, the internal market model could promote better management and loosen the gridlock in the NHS. It would be a tragedy if his ideas were not taken seriously, weighed in the balance, and tested in the small pilot schemes he advocates so powerfully. The conventional treatment for congestive heart failure is diuretics (either a thiazide or a loop diuretic), some form of potassium replacement, and digoxin. Digoxin is specifically indicated for the control of atrial fibrillation but is also widely used in patients with heart failure who are in sinus rhythm. For mild, moderate, and even severe heart failure this treatment is effective in most patients. Fluid overload producing either peripheral oedema or pulmonary congestion is controlled, and symptoms are improved. A clinical problem exists only when despite conventional treatment patients continue to have symptoms, usually shortness of breath or fatigue.
What further treatment should then be introduced? New inotropic drugs have been and are being investigated in the belief that a more powerful positive inotropic agent without the toxic side effects of digoxin might be valuable in heart failure. Vasodilators have also been studied, since unloading the heart might directly relieve symptoms and retard the progressive functional deterioration of myocardial muscle. Numerous reports of the acute and chronic haemodynamic effects of these drugs have been published, but few fulfil criteria advocated for clinical trials. We have reassessed the value of oral inotropic and vasodilator drugs in heart failure by analysing those papers which report randomised, blind, and controlled trials.
Review of published work
Thirty trials were identified in which a control group was included, patients were randomised, the assessment was double blind, and the duration exceeded 48 hours. Of these 30 trials, 10 reported on a positive inotropic drug, 18 on a vasodilator, and two on 13 blockers. The trials were evaluated in terms of diagnostic criteria, selection criteria, drug treatment, sample size, duration, withdrawals, and methods of assessment of the end point. Tables I and II In a study lasting six months hydralazine did not alter resting haemodynamics, exercise capacity, ejection fraction as asessed by radionuclide scanning, or exercise capacity.4 A later trial lasting 12 months failed to show a persistent increase of exercise capacity measured on a bicycle ergometer, but symptoms assessed by the New York Heart Association criteria improved in 11 out of 17 patients in the hydralazine treated group compared with seven out of 18 patients in the control group.5 Forty four per cent of patients initially included in the trial failed to complete the study. The clinical relevance of the difference between the groups is unclear.
In two out of five trials prazosin, an inhibitor of a adrenergic receptors, increased exercise capacity. lO In one of these trials 10 patients taking prazosin required an increase in treatment with diuretics as compared with one out of 12 in the placebo group.8 The other study was the only one to show unequivocal long term benefit with prazosin, in that exercise duration increased and left ventricular ejection fraction improved. ' Trimazosin improved exercise capacity and reduced symptoms," 12 but in one of these trials four out of 13 patients were not randomly allocated to treatment and the outcome of all patients was not assessed blindly. 12 Three trials of captopril13-l' and two of enalapril,6 '7 both angiotensin converting enzyme inhibitors, showed benefit to patients after long term treatment of heart failure. Captopril improved symptoms (New York Heart Association criteria), exercise duration, left ventricular ejection fraction, exercise haemodynamics, and maximal oxygen consumption. Treatment with diuretics was altered in both trials,'617 but in the larger and more convincing study treatment was increased in only one out of 16 patients treated with enalapril as compared with seven out of 14 in the control group. '6 Minoxidil caused an appreciable worsening of heart failure, increased the need for diuretics, and increased the incidence of ventricular arrhythmias. 8 The outcome was not assessed blindly.
The trials of inotropic drugs included three on digoxin,'9-2' two on amrinone, 2223 one on pirbuterol, four on prenalterol, and two on 13 blockers. Dobbs et al found that 16 of 46 patients deteriorated when placebo was substituted for digoxin, and concluded that treatment with digoxin was warranted in patients with heart failure.2' Thirteen patients with atrial fibrillation were included in the trial, but the report left unclear how many of the patients who deteriorated had atrial fibrillation. Eighteen patients were not receiving diuretics, and the aetiology of heart failure was heterogeneous, including 10 patients with bronchitis and emphysema. The end point was clinical deterioration. Body weight increased in the 16 patients who deteriorated while taking placebo and did not increase in those who did not deteriorate. How other treatments were altered during the trial was not made clear. Fleg et al found no effect on exercise duration or left ventricular function after withdrawal of digoxin.'9 Treatment allocation was not in random order. The drop out rate was 25%, which reduced the likelihood of detecting a clinically important difference from placebo. Lee et al reported that 14 out of 25 patients with heart failure in sinus rhythm deteriorated while taking placebo.20 Those who responded to digoxin were characterised by more severe heart failure and a third sound. Clinical improvement with digoxin was associated with a loss of body weight (p<001), and in most patients equal benefit might have been obtained by increase of diuretics alone. Only 10 patients were taking more than 80 mg frusemide, and three were receiving no diuretic at all.
A multicentre trial of amrinone selected 52 out of 173 "acute responders" for long term treatment. 23 No benefit was found after prolonged treatment in this selected group. Pirbuterol24 and prenalterol25-21 failed to improve exercise haemodynamics or exercise capacity.
Waagstein et al claimed on the basis of uncontrolled studies that patients with cardiomyopathy improved long term when treated with 13 blockers.2932 Neither of the two controlled trials published showed any benefit from 13 blockade in terms of exercise capacity or left ventricular function.33 34
Conclusions
Many papers have been published on the effects of newer inotropic or vasodilator drugs in the treatment of patients with heart failure. Often they have reported the haemodynamic consequences of acute administration of the drug. Some attempt to show that these acute haemodynamic changes are maintained after long term treatment and are accompanied by clinical improvement or an increase in treadmill exercise time. Few papers report controlled, double blind, and randomised trials. The apparent reluctance to undertake such trials is almost,certainly related to the predictable difficulties. The mortality from severe heart failure is high, so that patients are lost to the study if the end point is exercise tolerance. Deterioration of the patient due to progression of heart disease necessitates withdrawal from the trial. The need to increase diuretics during the trial complicates the interpretation of the results. Blinding may be difficult if drugs such as digoxin are to be used, and the use of digoxin complicates a study of an alleged inotropic drug. The aetiology of heart failure is rarely the same in all patients. Previous drug treatment may have a carryover effect in the trial. The end point for an exercise test may be breathlessness, fatigue, or even angina28 in different patients and be altered by the drug by different mechanisms.
In this paper we have reviewed the published studies in heart failure which have included a control group of patients. It is immediately apparent that the results from these selected trials do not support the enthusiastic claims from uncontrolled studies. 995 exercise testing as a means of assessing ability of patients to lead an acceptable if restricted life is not yet clear.
The response to treatment is commonly assessed not only by symptoms and exercise capacity but also by cardiac function (haemodynamics and ventricular ejection fraction). These should not be regarded as synonymous. Franciosa that its inotropic effect is small and limited by the appearance of toxicity so that any harmful effect due to overstimulation of the myocardium is minimised. Many withdrawal studies on digoxin have been undertaken and have shown the proportion of patients deteriorating to be from nil to 56%.4' Digoxin remains the only inotropic drug in which there is reasonable evidence of efficacy. What is less clear is whether the benefit derived from digoxin still accrues in patients optimally treated with diuretics.
The results of studies with vasodilating drugs are more complex. In one positive study of prazosin the diuretic dosage was altered.8 In a study on trimazosin the strict criteria for a double blind randomised trial were not fulfilled.'2 Only two studies, those by Aronow et al, show that a blockade increases exercise capacity.91' The evidence for the efficacy of nitrates is also not compelling, since in all three studies the diuretic dosage was altered. Hydralazine may be marginally superior to placebo in its ability to improve symptoms, though this effect may not be apparent until after one year of treatment.' Possible reasons for these disappointing effects of some vasodilators on exercise capacity are that drug tolerance developed long term by whatever mechanism, that symptoms were not determined solely by haemodynamic variables, and that, though vasodilatation often increases cardiac output, blood flow is increased to the skin and splanchnic circulation rather than altering the blood flow to exercising skeletal muscle. 42 The word "vasodilators" has been used to group together a variety of drugs with very different pharmacological properties. The concept of characterising drugs on the basis of haemodynamic effect may be misleading in a disease as complex as heart failure. Five studies have shown that angiotensin converting enzyme inhibitors are beneficial to patients with severe heart failure, and in these studies there was a correspondence between the improvement of the clinical state of the patient and the change in haemodynamics."5 The acute haemodynamic effect of these drugs is similar to that of other vasodilators. The reason why they are so advantageous in contrast with the other vasodilators is not known, but it may be due to specific effects on the kidney and peripheral circulation and to inhibition of the increase in plasma renin activity brought about by the use of high doses of diuretics. The haemodynamic changes long term may be partly a consequence of such effects rather than the direct cause of clinical improvement. It is also possible, though improbable, that the specific advantage of this class of drug is solely because the trials, having been undertaken more recently, have been better designed and include one large study.
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